Filtered By:
Infectious Disease: Hepatitis A
Vaccination: Hepatitis Vaccine
This page shows you your search results in order of date.
Order by Relevance | Date
Total 1195 results found since Jan 2013.
Vaccination coverage survey of children aged 1-3 years in Beijing, China, 2005-2021
CONCLUSION: The coverage level and service quality of routine immunization in Beijing were relatively high. However, as influenced by COVID-19 epidemics, both on-time and in-time vaccination rates decreased significantly, except for BCG and HepB. Under the background of COVID-19 pandemic, the keys to maintain high level of vaccination coverage include flexible immunization service time to ensure the guardians bringing their children for vaccination timely, and more attention from providers to the doses after children's first birthday.PMID:37709591 | DOI:10.1016/j.vaccine.2023.08.015
Source: Vaccine - September 14, 2023 Category: Allergy & Immunology Authors: Wen-Yan Ji Dong-Lei Liu Rui Yu Liang Miao Qian-Li Yuan Luo-Dan Suo Jian-Ping Yu Source Type: research
Assessment of Disease Burden and Immunization Rates for Vaccine-Preventable Diseases in People Living with HIV: The Korea HIV/AIDS Cohort Study
CONCLUSION: The burden of vaccine-preventable diseases was quite high in HIV-infected patients. Nadir CD4 T-cell counts, peak HIV viral loads, and the number of ART regimen change are significant factors related to vaccination. Considering the low vaccination rates for VPDs, there was a discordance between experts' opinions and real clinical practice in the medical field.PMID:37674339 | DOI:10.3947/ic.2023.0045
Source: Herpes - September 7, 2023 Category: Infectious Diseases Authors: Hye Seong Yunsu Choi Kyoung Hwan Ahn Jun Yong Choi Shin-Woo Kim Sang Il Kim Mee-Kyung Kee Bo Youl Choi Boyoung Park Hak Jun Hyun Jin Gu Yoon Ji Yun Noh Hee Jin Cheong Woo Joo Kim Joon Young Song Source Type: research
Immunogenicity and safety of Havisure < sup > TM < /sup > vaccine developed by Human Biologicals Institute in healthy subjects of 12 months to 49 years of age: A phase II/III, randomized, single blind, non-inferiority study
CONCLUSION: The study results indicate that the Havisure™ vaccine is immunogenic and safe when administered to healthy subjects of 12 months to 49 years of age, and is non-inferior to Havrix® Vaccine.PMID:37661535 | DOI:10.1016/j.vaccine.2023.08.084
Source: Vaccine - September 4, 2023 Category: Allergy & Immunology Authors: Sai Krishna Susarla Madhu Gupta Kheya Ghosh Uttam Sonali Palkar Ashish Ramachandra Dhongade K Siva Ram Prasad Vasudev Rajapantula M D Ravi N Pradeep M Satish B C Rajashakar G Sandhya L Rajendra Devi Prasad Sahoo Anand Kumar Kanakasapapathy Source Type: research
Impact of frequency and duration of freeze-dried inactivated tissue culture hepatitis A vaccine (Aimmugen ®) vaccination on antibody titers; a japanese cross-sectional study
CONCLUSIONS: Three doses of Aimmugen® are efficacious, but four or more doses induce more robust and sustained antibody production. Additionally, four or more doses may be effective when there is a need to ensure long-term immunity or risk of prolonged exposure.PMID:37620202 | DOI:10.1016/j.vaccine.2023.08.030
Source: Vaccine - August 24, 2023 Category: Allergy & Immunology Authors: Yohei Maki Naoki Edo Makoto Mizuguchi Mikihito Ikeda Masato Kitano Etsuko Kitagami Morichika Osa Shotaro Yamamoto Takunori Ogawa Takahiro Nakamura Akihiko Kawana Yoshifumi Kimizuka Source Type: research
Viral Hepatitis in Pregnancy: ACOG Clinical Practice Guideline No. 6
Obstet Gynecol. 2023 Sep 1;142(3):745-759. doi: 10.1097/AOG.0000000000005300.ABSTRACTPURPOSE: The purpose of this document is to describe the specific types of viral hepatitis, their implications during pregnancy, the risk of perinatal transmission, and issues related to both treatment and prevention of infection.TARGET POPULATION: Pregnant or postpartum women and individuals who screen positive for viral hepatitis infection. The onset of these conditions may have predated the perinatal period or may have occurred for the first time in pregnancy or the first year postpartum.METHODS: This guideline was developed using an a ...
Source: Obstetrics and Gynecology - August 17, 2023 Category: OBGYN Source Type: research
Impact of methotrexate treatment on vaccines immunogenicity in adult rheumatological patients - Lessons learned from the COVID-19 pandemic
Biomed Pharmacother. 2023 Aug 3;165:115254. doi: 10.1016/j.biopha.2023.115254. Online ahead of print.ABSTRACTDespite the development of new biological and synthetic targeted therapies, methotrexate remains one of the most commonly used immunomodulatory drugs in rheumatology. However, its effect on the immunogenicity of vaccines has been studied only to a limited extent until recently, resulting in the lack of clear guidelines on the use of methotrexate during vaccination. Significant progress was made during the COVID-19 pandemic due to the dynamic development of research on vaccines, including patients with autoimmune inf...
Source: Herpes - August 5, 2023 Category: Infectious Diseases Authors: Jakub Wro ński Marzena Ciechomska Ewa Kuca-Warnawin Source Type: research
